Chanouzas D, et al. - Researchers assessed survival, renal recovery, relapses, and adverse events in patients who had, or had not received methylprednisolone (MP), along with standard therapy for remission induction in severe ANCA associated vasculitis (AAV). This retrospective analysis included 114 consecutive patients with a new diagnosis of severe AAV (creatinine > 500 μmol/L or dialysis dependency) from five centres in Europe and the United States. The participants had received standard therapy (plasma exchange, cyclophosphamide and high-dose oral corticosteroids) for remission induction with or without pulse MP between 2000 and 2013. Findings revealed no possible clinical benefit of adding pulse intravenous MP to standard therapy for remission induction in severe AAV. Furthermore, this treatment strategy could be related to more episodes of infection and higher incidence of diabetes.